


# VALUTAZIONE DOSIMETRICA DEI PIANI DI CURA IN IMRT CON BOOST SIMULTANEO INTEGRATO PER IL TRATTAMENTO DI NEOPLASIE DEL RINOFARINGE LOCALMENTE AVANZATE

<sup>^</sup>A. Errico, <sup>^^</sup>**R. D'Agostino**, <sup>^</sup>A. Natuno, <sup>^</sup>D. Di Cosmo, <sup>^</sup>G. Squeo, <sup>^</sup>S. Carbone, <sup>^^</sup>A. De Zio, <sup>^^</sup>C. M. Malcangi, <sup>^^</sup>A. Lamacchia, <sup>^^</sup>A. M. Cicoria, <sup>^^</sup>A. Favia, <sup>^</sup>S. Bambace  
*U.O.C. Radioterapia - Osp. Dimiccoli, Barletta*



# NEOPLASIE DEL RINOFARINGE



## INCIDENZA

- **BASSA:** USA, Europa (0,2-0,5 casi/100.000 abitanti)
- **ALTA:** Cina meridionale, Hong Kong (25-50 casi/100.000 abitanti)

Africa settentrionale (8-12 casi /100.000 abitanti)

## EZIOLOGIA


- Abitudini voluttuarie: fumo di tabacco, consumo di alcool
- Abitudini alimentari
- Infezioni virali: EBV

## ISTOLOGIA

- **CARCINOMA (90%):**  
Squamoso cheratinizzante  
Squamoso non cheratinizzante  
Indifferenziato
- **LINFOMA (10%)**

# NEOPLASIE DEL RINOFARINGE

## ANATOMIA E VIE DI DIFFUSIONE



Per contiguità



IN ALTO

osso sfenoide

base cranio

IN AVANTI

cavità nasale

LATERALMENTE

tube uditive

nervi cranici

a. carotide

v. giugulare int.

Per via linfatica



linfonodi laterocervicali

# NEOPLASIE DEL RINOFARINGE

## SINTOMI

- EPISTASSI
- OTALGIA
- OSTRUZIONE NASALE
- DEFICIT NERVI CRANICI
- TURBE OLFATTIVE




# NEOPLASIE DEL RINOFARINGE: TRATTAMENTO



National  
Comprehensive  
Cancer  
Network®

**NCCN Guidelines Version 2.2014**  
**Cancer of the Nasopharynx**

[NCCN Guidelines Index](#)  
[Head and Neck Table of Contents](#)  
[Discussion](#)



<sup>b</sup>See Principles of Radiation Therapy (NASO-A).

<sup>c</sup>See Principles of Systemic Therapy (CHEM-A).

<sup>d</sup>When using concurrent chemotherapy/RT, the preferred agent is cisplatin (category 1). See Principles of Systemic Therapy (CHEM-A).

<sup>e</sup>See Discussion on induction chemotherapy.


<sup>f</sup>Can be used for select patients with distant metastasis in limited site or with small tumor burden, or for patients with symptoms in the primary or any nodal site.

<sup>g</sup>See Principles of Surgery (SURG-A).


Note: All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

# NEOPLASIE DEL RINOFARINGE

L'IMRT rappresenta il *gold standard* nel trattamento delle neoplasie del rinofaringe



ottimizzare la distribuzione di dose al target



minimizzare la dose agli organi a rischio



# NEOPLASIE DEL RINOFARINGE



## HEAD AND NECK CANCER SYMPOSIUM

Int. J. Radiation Oncology Biol. Phys., Vol. 69, No. 2, Supplement, pp. S115-S117, 2007

Copyright © 2007 Elsevier Inc.

Printed in the USA. All rights reserved

0360-3016/07/\$-see front matter

## NASOPHARYNGEAL CANCER: ADVANCES IN RADIOTHERAPY

ANNE W. M. LEE, F.R.C.R.

Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong

Nasopharyngeal cancer (NPC) is one of the greatest challenges for oncologists. Because of the deep-seated anatomic location and the proximity to critical structures, radical surgical resection is most difficult. This highly malignant cancer was invariably lethal until the advent of radiotherapy (RT). The first reports of long survivors (25% at 5 years) in the mid-1960s marked the first major breakthrough. Megavoltage RT has since become the mainstay of treatment, but the therapeutic margin is notoriously narrow.

Meticulous attention to every single step in the RT process is important, particularly when using an increasingly conformal technique. The first fundamental step is accurate delineation of the gross tumor extent. Fusion of magnetic resonance images with planning computed tomography is indicated. Positron emission tomography is being increasingly used, not only for better detection of distant metastases, but also for depiction of locoregional tumor metabolic activity for supplementary information.

Optimization of dose fractionation is crucial. Although NPC is radiosensitive, a significant dose response has been suggested by retrospective data. The general consensus is that a total dose of 70 Gy or above is needed for the gross tumor and 50–60 Gy for elective treatment of potential at-risk sites. One method of achieving dose escalation is to give

Table 1. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: methods and results from different centers

Variable	Study				
	UCSF (10, 11)	MSKCC (12)	PWH (13)	QMH (14)	QMH (15)
Patients (n)	118	74	63	50	50
T stage	All	All	All	T1-T2	T3-T4
Median follow-up (mo)	30	35	29	14	25
RT regimen					
PTV-G (margin around GTV; mm)		5–10	2		
Total dose (Gy)	70	70.2	66	68–70	76
Dose/fraction (Gy)	2.12	2.34	2	2–2.06	2.17
Additional treatment (%)					
Accelerated fractionation	—	80	—	—	—
Boost	22	—	56	—	—
Chemotherapy	90	93	30	0	68
Tumor control					
Time point (y)	4	3	3	2	2
Local control (%)	96	91	92	100	96
Nodal control (%)	98	93	98	94	—
Distant control (%)	72	78	79	94	94
Overall survival (%)	74	83	90	NR	92
Late toxicities (%)					
Xerostomia (Grade ≥2)	2* (2 y)	32 (4 y)	23 (2 y)	—	—
Deafness (Grade >2)	7%*	>15%	15	—	42
Fibrosis (Grade >2)	—	—	11	—	14
Dysphagia (Grade >2)	1*	—	5	—	—
Hypopituitarism	—	—	23	—	—
Osteonecrosis	0.8	—	2	—	—
Temporal lobe necrosis	0.8	—	3	—	4
Torrential epistaxis	0.8*	—	—	—	4

Abbreviations: UCSF = University of California, San Francisco; MSKCC = Memorial Sloan-Kettering Cancer Center; PWH = Prince of Wales Hospital (Hong Kong); QMH = Queen Mary Hospital (Hong Kong); PTV-G = planning target volume for gross tumor; GTV = gross tumor volume.

\* According to data reported by Lee *et al.* (10) in 2002.

# NEOPLASIE DEL RINOFARINGE







Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 1, pp. 145-157, 2003  
Copyright © 2003 Elsevier Inc.  
the USA. All rights reserved  
0-3016/03/\$-see front matter

## 3D-CRT

### INTENSITY-MODULATED RADIOTHERAPY IN NASOPHARYNGEAL CARCINOMA: DOSIMETRIC ADVANTAGE OVER CONVENTIONAL PLANS AND FEASIBILITY OF DOSE ESCALATION

MICHAEL K. M. KAM, F.R.C.R., RICKY M. C. CHAU, M.Sc., JOYCE SUEN, M.B.Ch.B.,  
PETER H. K. CHOI, F.R.C.R., AND PETER M. L. TEO, M.D., F.R.C.R.

Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China



# NEOPLASIE DEL RINOFARINGE



Int. J. Radiation Oncology Biol. Phys., Vol. 75, No. 5, pp. 1481–1486 2009

Copyright © 2009 Elsevier Inc.

Printed in the USA. All rights reserved

0360-3016/09/\$—see front matter

## CLINICAL INVESTIGATION

## Head and Neck

### TREATMENT OF NASOPHARYNGEAL CARCINOMA USING INTENSITY-MODULATED RADIOTHERAPY—THE NATIONAL CANCER CENTRE SINGAPORE EXPERIENCE

IVAN WENG-KEONG THAM, FRCR.,\*<sup>†</sup> SIEW WAN HEE, MSc.,<sup>†</sup> RICHARD MING-CHERT YEO, FRCR.,\*  
 PATEMAH BTE SALLEH, CMD.,\* JAMES LEE, PhD.,\* TERENCE WEE-KIAT TAN, FRCR.,\*  
 KAM WENG FONG, FRCR.,\* EU TIONG CHUA, FRCR.,\* AND  
 JOSEPH TIEN-SENG WEE, FRCR.\*<sup>†</sup>

\*Department of Radiation Oncology, and <sup>†</sup>Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore

Table 3. One- and three-year survival rates

Type	Events/N	1-year rate		3-year rate	
		%	SE	%	SE
All patients					
Overall survival	14/195	98.4	0.009	94.3	0.018
Local recurrence-free survival	19/195	96.8	0.013	89.6	0.024
Distant relapse-free survival	19/195	96.8	0.013	89.2	0.024
Disease-free survival	41/195	93.7	0.018	79	0.031
Patients with complete response					
Overall survival	10/188	98.9	0.008	96.5	0.014
Local recurrence-free survival	12/188	NE	NE	93.1	0.021
Distant relapse-free survival	16/188	97.8	0.011	90.6	0.023
Disease-free survival	34/188	96.7	0.013	82.1	0.029

Table 4. Frequency (%) of acute toxicity

Toxicity	Chemotherapy			No chemotherapy		
	Grade 0–2	Grade 3	Grade 4	Grade 0–2	Grade 3	Grade 4
Desmaturic	102 (98)	2 (2)	0	77 (100)	0	0
Mucositis	75 (71)	30 (29)	0	63 (80)	15 (20)	0
Dysphagia	83 (79)	22 (21)	0	73 (92)	6 (8)	0
Xerostomia	101 (97)	3 (3)	—	77 (100)	0	—
Hemoglobin nadir	105 (95)	5 (5)	0			
Total white count nadir	69 (63)	37 (34)	4 (4)			
Neutrophil count nadir	73 (66)	33 (30)	4 (4)			
Platelet count nadir	107 (97)	3 (3)	0			

# NEOPLASIE DEL RINOFARINGE: TRATTAMENTO

## PRINCIPLES OF RADIATION THERAPY<sup>1</sup>

### **DEFINITIVE**

RT Alone (preferred if no chemotherapy is being used)

#### • PTV

- High risk: Primary tumor and involved lymph nodes (this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))
  - 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday-Friday in 6-7 weeks
- Intermediate and low risk: Sites of suspected subclinical spread
  - 44 Gy (2.0 Gy/fraction) to 60 Gy (1.6 Gy/fraction)<sup>2</sup>

### **CONCURRENT CHEMORADIATION:**<sup>3</sup>

(preferred for patients eligible for chemotherapy)

#### • PTV

- High risk: typically 70 Gy (2.0 Gy/fraction)
- Intermediate and low risk: 44 Gy (2.0 Gy/fraction) to 60 Gy (1.6 Gy/fraction)<sup>2</sup>

IMRT is preferred over 3D conformal RT in cancer of the nasopharynx to minimize dose to critical structures.

<sup>1</sup>See [Radiation Techniques \(RAD-A\)](#) and [Discussion](#).

<sup>2</sup>Suggest 44-54 Gy in 3D conformal RT and 54-60 Gy in IMRT due to dose painting (dependent upon dose per fraction).

<sup>3</sup>See [Principles of Systemic Therapy \(CHEM-A\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

# IL NOSTRO STUDIO

**SCOPO:** valutare la qualità dosimetrica dei piani di trattamento in modalità SIB-IMRT di neoplasie rinofaringee localmente avanzate eseguiti c/o l'U.O. Radioterapia dell'Osp. Dimiccoli di Barletta

**MATERIALI E METODI:** da Febbraio 2010 a Febbraio 2014 sono stati trattati 10 pz mediante radioterapia SIB-IMRT, associata a chemio concomitante a base di CDDP.

## 3 volumi target


PTV1:T,N+ ➡ 66/69,96Gy

PTV2:N ad alto rischio di malattia subclinica ➡ 60Gy

PTV3 :N a basso rischio di malattia subclinica ➡ 54Gy

## Organi a rischio

Midollo spinale, tronco encefalico, parotidi, coclee, laringe, chiasma ottico




# IL NOSTRO STUDIO



PTV 69,96



PTV 60






PTV 54

# IL NOSTRO STUDIO

## STRATEGIE RT


Tutti i pazienti sono stati sottoposti a TC PET di fusione per la delineazione dei volumi bersaglio



# IL NOSTRO STUDIO

## CONTROLLI IGRT


Tutti i pazienti sono stati sottoposti a controlli di *setup* mediante *imaging* a kV giornaliero e *cone-beam* una volta a settimana



# IL NOSTRO STUDIO

Di ogni piano è stato calcolato:

- L'indice di conformità (CI, *conformity index*)
- L'indice di omogeneità (HI, *homogeneity index*)



# IL NOSTRO STUDIO



Int. J. Radiation Oncology Biol. Phys., Vol. 64, No. 2, pp. 333–342, 2006  
Copyright © 2006 Elsevier Inc.  
Printed in the USA. All rights reserved  
0360-3016/06/\$—see front matter

Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 2, pp. 573–581, 2003  
Copyright © 2003 Elsevier Inc.  
Printed in the USA. All rights reserved  
0360-3016/03/\$—see front matter

## CRITICAL REVIEW

### CONFORMITY INDEX: A REVIEW

LOIC FEUVRET, M.D.,\* GEORGES NOËL, M.D.,\* JEAN-JACQUES MAZERON, M.D., Ph.D.,<sup>†</sup>  
AND PIERRE BEY, M.D.<sup>‡</sup>

\*Institut Curie, Orsay, France; <sup>†</sup>Pitié Salpêtrière Hospital, Paris, France; <sup>‡</sup>Institut Curie, Paris, France

$$Conformity\ Index_{RTOG} = \frac{V_{RI}}{TV} \quad (1c)$$

where  $V_{RI}$  = reference isodose volume, and  $TV$  = target volume.

The RTOG “conformity index” (Eq.1c) is easy to interpret. A conformity index equal to 1 corresponds to ideal conformation. A conformity index greater than 1 indicates that the irradiated volume is greater than the target volume and includes healthy tissues. If the conformity index is less than 1, the target volume is only partially irradiated. According to RTOG guidelines, ranges of conformity index values have been defined to determine the quality of conformation, because a value of 1 is rarely obtained. If the

## PHYSICS CONTRIBUTION

### SIMULTANEOUS INTEGRATED BOOST INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK SQUAMOUS CELL CARCINOMAS. I: DOSIMETRIC RESULTS


QIUWEN WU, Ph.D., RADHE MOHAN, Ph.D., MONICA MORRIS, M.D., ANDREW LAUVE, M.D., AND  
RUPERT SCHMIDT-ULLRICH, M.D.

Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA


$$HI = \frac{D_2 - D_{98}}{D_{prescription}} \times 100\% \quad (1)$$

Lower HI values are indicative of a more homogeneous target dose.

# IL NOSTRO STUDIO




CI mediano per il PTV1 è  
1,40 (range 1,20- 1,60)



Il CI mediano per il PTV2  
è 1,50 ( range 1,40- 1,70)

# IL NOSTRO STUDIO




Il CI mediano per il PTV3 è  
1,50 (range 1,20- 1,80)

**Per tutti i PTV  
considerati l'indice  
di conformità  
mediano è compreso  
in tali limiti**


Int. J. Radiation Oncology Biol. Phys., Vol. 64, No. 2, pp. 333-342, 2006  
Copyright © 2006 Elsevier Inc.  
Printed in the USA. All rights reserved  
0360-3016/06/\$ - see front matter

formation, because a value of 1 is rarely obtained. If the conformity index is situated between 1 and 2, treatment is considered to comply with the treatment plan; an index between 2 and 2.5, or 0.9 and 1, is considered to be a minor violation, and an index less than 0.9 or more than 2.5 is considered to be a major violation. However, this index


# IL NOSTRO STUDIO




L'HI mediano per il PTV1 è 0,08  
(range 0,06- 0,10)




L'HI mediano per il PTV2 è  
0,14 (range 0,07- 0,20)



# IL NOSTRO STUDIO



L'HI mediano per il PTV 3 è  
0,19 (range 0,07- 0,30)



# IL NOSTRO STUDIO

## RISULTATI

### USE OF NORMAL TISSUE COMPLICATION PROBABILITY MODELS IN THE CLINIC


LAWRENCE B. MARKS, M.D.,\* ELLEN D. YORKE, Ph.D.,<sup>†</sup> ANDREW JACKSON, Ph.D.,<sup>‡</sup>  
 RANDALL K. TEN HAKEN, Ph.D.,<sup>‡</sup> LOUIS S. CONSTINE, M.D.,<sup>§</sup> AVRAHAM EISBRUCH, M.D.,<sup>‡</sup>  
 SOREN M. BENTZEN, Ph.D.,<sup>||</sup> JIHO NAM, M.D.,\* AND JOSEPH O. DEASY, Ph.D.<sup>‡</sup>

Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)\*


Organ	Volume segmented	Irradiation type (partial organ unless otherwise stated) <sup>†</sup>	Endpoint	Dose (Gy), or dose/volume parameters <sup>†</sup>	Rate (%)	Notes on dose/volume parameters
Brain stem	Whole organ	Whole organ	Permanent cranial neuropathy or necrosis	Dmax <54	<5	
	Whole organ	3D-CRT	Permanent cranial neuropathy or necrosis	D1-10 cc <sup>‡</sup> ≤59	<5	
	Whole organ	3D-CRT	Permanent cranial neuropathy or necrosis	Dmax <64	<5	Point dose <<1 cc
	Whole organ	SRS (single fraction)	Permanent cranial neuropathy or necrosis	Dmax <12.5	<5	For patients with acoustic tumors
Spinal cord	Partial organ	3D-CRT	Myelopathy	Dmax = 50	0.2	Including full cord cross-section
	Partial organ	3D-CRT	Myelopathy	Dmax = 60	5	
	Partial organ	3D-CRT	Myelopathy	Dmax = 69	50	
	Partial organ	SRS (single fraction)	Myelopathy	Dmax = 13	1	Partial cord cross-section irradiated
	Partial organ	SRS (hypofraction)	Myelopathy	Dmax = 20	1	3 fractions, partial cord cross-section irradiated

# IL NOSTRO STUDIO

## RISULTATI



La mediana della D max al tronco encefalico è 49,6 Gy (range 45,4 Gy - 53,9 Gy)




La mediana della D max al midollo spinale è 41,9 Gy (range 38,5 Gy - 45,3 Gy)

# IL NOSTRO STUDIO

Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)\*


Organ	Volume segmented	Irradiation type (partial organ unless otherwise stated) <sup>1</sup>	Endpoint	Dose (Gy), or dose/volume parameters <sup>1</sup>	Rate (%)	Notes on dose/volume parameters
Larynx	Whole organ	3D-CRT	Vocal dysfunction	D <sub>max</sub> <66	<20	With chemotherapy, based on single study (see Section A4.2 in paper)
	Whole organ	3D-CRT	Aspiration	Mean dose <50	<30	With chemotherapy, based on single study (see Fig. 1 in paper)
	Whole organ	3D-CRT	Edema	Mean dose <44	<20	Without chemotherapy, based on single study in patients without larynx cancer**
	Whole organ	3D-CRT	Edema	V50 <27%	<20	Without chemotherapy, based on single study in patients without larynx cancer**
Cochlea	Whole organ	3D-CRT	Sensory neural hearing loss	Mean dose ≤45	<30	Mean dose to cochlea, hearing at 4 kHz
	Whole organ	SRS (single fraction)	Sensory neural hearing loss	Prescription dose ≤14	<25	Serviceable hearing



La mediana della D media al laringe è 41,3 Gy (range 34,6 Gy- 48,0 Gy)


# IL NOSTRO STUDIO

## RISULTATI



D media coclea omolat

La mediana della D media alla coclea omolaterale è 38,1 Gy (range 30,1 Gy - 46,0 Gy)




D media coclea controlat

La mediana della D media alla coclea controlaterale è 27,8 Gy (range 21,2 Gy - 34,3 Gy)

# IL NOSTRO STUDIO

Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)\*

Organ	Volume segmented	Irradiation type (partial organ unless otherwise stated) <sup>1</sup>	Endpoint	Dose (Gy), or dose/volume parameters <sup>1</sup>	Rate (%)	Notes on dose/volume parameters
Optic nerve / chiasm	Whole organ	3D-CRT	Optic neuropathy	Dmax <55	<3	Given the small size, 3DCRT is often whole organ <sup>12</sup>
	Whole organ	3D-CRT	Optic neuropathy	Dmax 55-60	3-7	
	Whole organ	3D-CRT	Optic neuropathy	Dmax >60	>7-20	
	Whole organ	SRS (single fraction)	Optic neuropathy	Dmax <12	<10	



La mediana della D max al chiasma ottico è 24,1 Gy (range 3,2 Gy – 45,0 Gy)

# IL NOSTRO STUDIO

Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)\*

Organ	Volume segmented	Irradiation type (partial organ unless otherwise stated) <sup>†</sup>	Endpoint	Dose (Gy), or dose/volume parameters <sup>‡</sup>	Rate (%)	Notes on dose/volume parameters
Parotid	Bilateral whole parotid glands	3D-CRT	Long term parotid salivary function reduced to <25% of pre-RT level	Mean dose <25	<20	For combined parotid glands <sup>¶</sup>
	Unilateral whole parotid gland	3D-CRT	Long term parotid salivary function reduced to <25% of pre-RT level	Mean dose <20	<20	For single parotid gland. At least one parotid gland spared to <20 Gy <sup>¶</sup>

La mediana della D media alla parotide omolaterale è 28,2 Gy (range 22,4 Gy - 34 Gy)  
La mediana alla parotide controlaterale è 22,7Gy (range 18,5 Gy - 26,9 Gy)

# IL NOSTRO STUDIO

## CONCLUSIONI

I risultati della nostra analisi dimostrano l'adeguatezza del piano di trattamento IMRT-SIB nell'assicurare la corretta e omogenea distribuzione di dose ai volumi irradiati simultaneamente e nel minimizzare l'estensione delle alte dosi nei tessuti sani circostanti.